Study on doxorubicin and carboplatin co-loaded liposome in the treatment of ovarian cancer ascites
Objective To study the treatment of ovarian cancer ascites with doxorubicin and carboplatin co-loaded liposomes.Methods The doxorubicin(DOX)and carboplatin(CBP)co-loaded liposomes(DOX/CBP-Lip)were prepared by thin film dispersion method combined with ammonium sulfate gradient method.Then the liposomes were characterized by particle size,Zeta potential,encapsulation efficiency,drug loading and in vitro drug release.In addition,the efficacy of the co-loaded liposomes in vivo was further evaluated.The body weight,abdominal circumference and survival rate were used as indicators.Results The particle size of DOX/CBP-Lip was 177.90 nm,and the Zeta potential was-32.63 mV.Moreover,the encapsulation efficiency(EE)of CBP was about 49.04%,and the drug loading(DL)of DOX was about2.52%.More importantly,the in vitro drug release results indicated that DOX/CBP-Lip had the certain sustained release effect.At the same dose,DOX/CBP-Lip showed a synergistic antitumor effect on OVCAR3 cells,and played a synergistic role in enhancing the antitumor activity of drugs and reducing drug toxicity.Conclusion The combined administration of DOX and CBP could improve the symptoms of ascites caused by ovarian cancer and reduce the toxicity of DOX and CBP.The dosage form provides a reference for the combined use of anti-tumor drugs in the treatment of ascites caused by tumors.
doxorubicincarboplatinliposomecombined administrationovarian cancer ascites
NETL
NSTL
万方数据
维普
